Regardless of the mutational heterogeneity within these malignant tumors, inactivating alterations in the TP53 gene are frequent changes detected in MPNST (up to 25%), which result in a loss of DNA damage response, increasing genomic instability and promoting tumor aggressiveness [36]. This evidence concerns the gene TP53 and malignant peripheral nerve sheath tumor.